keyword
https://read.qxmd.com/read/38717161/evaluation-of-copanlisib-in-combination-with-eribulin-in-triple-negative-breast-cancer-patient-derived-xenograft-models
#1
JOURNAL ARTICLE
Zhanfang Guo, Jingqin Luo, R Jay Mashl, Jeremy Hoog, Piyush Maiti, Nikki Fettig, Sherri R Davies, Rebecca Aft, Jason M Held, Ramaswamy Govindan, Li Ding, Shunqiang Li, Cornelius von Morze, Gerburg M Wulf, Kooresh I Shoghi, Cynthia X Ma
The phosphoinositide 3-kinase (PI3K) pathway regulates essential cellular functions and promotes chemotherapy resistance. Activation of PI3K pathway signaling is commonly observed in triple negative breast cancer (TNBC). However previous studies that combined PI3K pathway inhibitors with taxane regimens have yielded inconsistent results. We therefore set out to examine whether the combination of copanlisib, a clinical grade pan-PI3K inhibitor, and eribulin, an antimitotic chemotherapy approved for taxane-resistant metastatic breast cancer, improves the anti-tumor effect in TNBC...
May 8, 2024: Cancer Res Commun
https://read.qxmd.com/read/38699598/pharmacological-p38-mapk-inhibitor-sb203580-enhances-aml-stem-cell-line-kg1a-chemosensitivity-to-daunorubicin-by-promoting-late-apoptosis-cell-growth-arrest-in-s-phase-and-mir-328-3p-upregulation
#2
JOURNAL ARTICLE
Sara Bahattab, Ali Assiri, Yazeid Alhaidan, Thadeo Trivilegio, Rehab AlRoshody, Sarah Huwaizi, Bader Almuzzaini, Abir Alamro, Manal Abudawood, Zeyad Alehaideb, Sabine Matou-Nasri
Acute myeloid leukaemia (AML) is characterized by uncontrolled proliferation of myeloid progenitor cells and impaired maturation, leading to immature cell accumulation in the bone marrow and bloodstream, resulting in hematopoietic dysfunction. Chemoresistance, hyperactivity of survival pathways, and miRNA alteration are major factors contributing to treatment failure and poor outcomes in AML patients. This study aimed to investigate the impact of the pharmacological p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580 on the chemoresistance potential of AML stem cell line KG1a to the therapeutic drug daunorubicin (DNR)...
June 2024: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://read.qxmd.com/read/38683735/reverse-phase-protein-microarrays-for-overexpressed-escherichia-coli-lysates-reveal-a-novel-tyrosine-kinase
#3
JOURNAL ARTICLE
Batuhan Birol Keskin, Chien-Sheng Chen, Pei-Shan Tsai, Pin-Xian Du, John Harvey M Santos, Guan-Da Syu
Tyrosine phosphorylation is one of the most important posttranslational modifications in bacteria, linked to regulating growth, migration, virulence, secondary metabolites, biofilm formation, and capsule production. Only two tyrosine kinases (yccC (etk) and wzc) have been identified in Escherichia coli . The investigation by similarity has not revealed any novel BY-kinases in silico so far, most probably due to their sequence and structural variability. Here we developed a reverse-phase protein array from 4126 overexpressed E...
April 29, 2024: Analytical Chemistry
https://read.qxmd.com/read/38672531/chromatin-profiles-are-prognostic-of-clinical-response-to-bortezomib-containing-chemotherapy-in-pediatric-acute-myeloid-leukemia-results-from-the-cog-aaml1031-trial
#4
JOURNAL ARTICLE
Anneke D van Dijk, Fieke W Hoff, Yihua Qiu, Stefan E Hubner, Robin L Go, Vivian R Ruvolo, Amanda R Leonti, Robert B Gerbing, Alan S Gamis, Richard Aplenc, Edward A Kolb, Todd A Alonzo, Soheil Meshinchi, Eveline S J M de Bont, Terzah M Horton, Steven M Kornblau
The addition of the proteasome inhibitor bortezomib to standard chemotherapy did not improve survival in pediatric acute myeloid leukemia (AML) when all patients were analyzed as a group in the Children's Oncology Group phase 3 trial AAML1031 (NCT01371981). Proteasome inhibition influences the chromatin landscape and proteostasis, and we hypothesized that baseline proteomic analysis of histone- and chromatin-modifying enzymes (HMEs) would identify AML subgroups that benefitted from bortezomib addition. A proteomic profile of 483 patients treated with AAML1031 chemotherapy was generated using a reverse-phase protein array...
April 9, 2024: Cancers
https://read.qxmd.com/read/38657142/parallel-genetic-screens-identify-nuclear-envelope-homeostasis-as-a-key-determinant-of-telomere-entanglement-resolution-in-fission-yeast
#5
JOURNAL ARTICLE
Rishi Kumar Nageshan, Nevan Krogan, Julia Promisel Cooper
In fission yeast lacking the telomere binding protein, Taz1, replication forks stall at telomeres, triggering deleterious downstream events. Strand invasion from one taz1Δ telomeric stalled fork to another on a separate (non-sister) chromosome leads to telomere entanglements, which are resolved in mitosis at 32°C; however, entanglement resolution fails at ≤20°C, leading to cold-specific lethality. Previously, we found that loss of the mitotic function of Rif1, a conserved DNA replication and repair factor, suppresses cold sensitivity by promoting resolution of entanglements without affecting entanglement formation...
April 25, 2024: G3: Genes—Genomes—Genetics
https://read.qxmd.com/read/38558423/vdx-111-a-novel-small-molecule-induces-necroptosis-to-inhibit-ovarian-cancer-progression
#6
JOURNAL ARTICLE
Christianne Persenaire, Beatrice Babbs, Tomomi M Yamamoto, Morgan Nebbia, Kimberly R Jordan, Sarah Adams, James R Lambert, Benjamin G Bitler
Epithelial ovarian cancers that are nonhomologous recombination deficient, as well as those that are recurrent and in a platinum-resistant state, have limited therapeutic options. The objectives of this study were to characterize the mechanism of action and investigate the therapeutic potential of a small molecule, VDX-111, against ovarian cancer. We examined the ability of VDX-111 to inhibit the growth of a panel of ovarian cancer cell lines, focusing on BRCA wild-type lines. We found that VDX-111 causes a dose-dependent loss of cell viability across ovarian cancer cell lines...
April 1, 2024: Molecular Carcinogenesis
https://read.qxmd.com/read/38539515/pip4k2b-protein-regulation-by-nsd1-in-hpv-negative-head-and-neck-squamous-cell-carcinoma
#7
JOURNAL ARTICLE
Iuliia Topchu, Igor Bychkov, Ekaterina Roshchina, Petr Makhov, Yanis Boumber
Head and neck squamous cell carcinoma (HNSCC) ranks among the most prevalent global cancers. Despite advancements in treatments, the five-year survival rate remains at approximately 66%. The histone methyltransferase NSD1, known for its role in catalyzing histone H3 lysine 36 di-methylation (H3K36me2 ), emerges as a potential oncogenic factor in HNSCC. Our study, employing Reverse Phase Protein Array (RPPA) analysis and subsequent validation, reveals that PIP4K2B is a key downstream target of NSD1. Notably, PIP4K2B depletion in HNSCC induces downregulation of the mTOR pathway, resulting in diminished cell growth in vitro...
March 17, 2024: Cancers
https://read.qxmd.com/read/38531950/proteomics-for-optimizing-therapy-in-acute-myeloid-leukemia-venetoclax-plus-hypomethylating-agents-versus-conventional-chemotherapy
#8
JOURNAL ARTICLE
Eduardo Sabino de Camargo Magalhães, Stefan Edward Hubner, Brandon Douglas Brown, Yihua Qiu, Steven Mitchell Kornblau
The use of Hypomethylating agents combined with Venetoclax (VH) for the treatment of Acute Myeloid Leukemia (AML) has greatly improved outcomes in recent years. However not all patients benefit from the VH regimen and a way to rationally select between VH and Conventional Chemotherapy (CC) for individual AML patients is needed. Here, we developed a proteomic-based triaging strategy using Reverse-phase Protein Arrays (RPPA) to optimize therapy selection. We evaluated the expression of 411 proteins in 810 newly diagnosed adult AML patients, identifying 109 prognostic proteins, that divided into five patient expression profiles, which are useful for optimizing therapy selection...
March 26, 2024: Leukemia
https://read.qxmd.com/read/38509064/combined-kras-mapk-pathway-inhibitors-and-her2-directed-drug-conjugate-is-efficacious-in-pancreatic-cancer
#9
JOURNAL ARTICLE
Ashenafi Bulle, Peng Liu, Kuljeet Seehra, Sapana Bansod, Yali Chen, Kiran Zahra, Vikas Somani, Iftikhar Ali Khawar, Hung-Po Chen, Paarth B Dodhiawala, Lin Li, Yutong Geng, Chia-Kuei Mo, Jay Mahsl, Li Ding, Ramaswamy Govindan, Sherri Davies, Jacqueline Mudd, William G Hawkins, Ryan C Fields, David G DeNardo, Deborah Knoerzer, Jason M Held, Patrick M Grierson, Andrea Wang-Gillam, Marianna B Ruzinova, Kian-Huat Lim
Targeting the mitogen-activated protein kinase (MAPK) cascade in pancreatic ductal adenocarcinoma (PDAC) remains clinically unsuccessful. We aim to develop a MAPK inhibitor-based therapeutic combination with strong preclinical efficacy. Utilizing a reverse-phase protein array, we observe rapid phospho-activation of human epidermal growth factor receptor 2 (HER2) in PDAC cells upon pharmacological MAPK inhibition. Mechanistically, MAPK inhibitors lead to swift proteasomal degradation of dual-specificity phosphatase 6 (DUSP6)...
March 20, 2024: Nature Communications
https://read.qxmd.com/read/38463169/comparison-of-rna-seq-and-microarray-in-the-prediction-of-protein-expression-and-survival-prediction
#10
JOURNAL ARTICLE
Won-Ji Kim, Bo Ram Choi, Joseph J Noh, Yoo-Young Lee, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Chel Hun Choi
Gene expression profiling using RNA-sequencing (RNA-seq) and microarray technologies is widely used in cancer research to identify biomarkers for clinical endpoint prediction. We compared the performance of these two methods in predicting protein expression and clinical endpoints using The Cancer Genome Atlas (TCGA) datasets of lung cancer, colorectal cancer, renal cancer, breast cancer, endometrial cancer, and ovarian cancer. We calculated the correlation coefficients between gene expression measured by RNA-seq or microarray and protein expression measured by reverse phase protein array (RPPA)...
2024: Frontiers in Genetics
https://read.qxmd.com/read/38429335/phosphorylation-regulates-tau-s-phase-separation-behavior-and-interactions-with-chromatin
#11
JOURNAL ARTICLE
Lannah S Abasi, Nesreen Elathram, Manasi Movva, Amar Deep, Kevin D Corbett, Galia T Debelouchina
Tau is a microtubule-associated protein often found in neurofibrillary tangles (NFTs) in the brains of patients with Alzheimer's disease. Beyond this context, mounting evidence suggests that tau localizes into the nucleus, where it may play a role in DNA protection and heterochromatin regulation. The molecular mechanisms behind these observations are currently unclear. Using in vitro biophysical experiments, here we demonstrate that tau can undergo liquid-liquid phase separation (LLPS) with DNA, mononucleosomes, and reconstituted nucleosome arrays under low salt conditions...
March 1, 2024: Communications Biology
https://read.qxmd.com/read/38412255/multiomic-profiling-of-breast-cancer-cells-uncovers-stress-mapk-associated-sensitivity-to-akt-degradation
#12
JOURNAL ARTICLE
Emily C Erickson, Inchul You, Grace Perry, Aurelien Dugourd, Katherine A Donovan, Claire Crafter, Jeffrey W Johannes, Stuart Williamson, Jennifer I Moss, Susana Ros, Robert E Ziegler, Simon T Barry, Eric S Fischer, Nathanael S Gray, Ralitsa R Madsen, Alex Toker
More than 50% of human tumors display hyperactivation of the serine/threonine kinase AKT. Despite evidence of clinical efficacy, the therapeutic window of the current generation of AKT inhibitors could be improved. Here, we report the development of a second-generation AKT degrader, INY-05-040, which outperformed catalytic AKT inhibition with respect to cellular suppression of AKT-dependent phenotypes in breast cancer cell lines. A growth inhibition screen with 288 cancer cell lines confirmed that INY-05-040 had a substantially higher potency than our first-generation AKT degrader (INY-03-041), with both compounds outperforming catalytic AKT inhibition by GDC-0068...
February 27, 2024: Science Signaling
https://read.qxmd.com/read/38409909/harnessing-the-potential-of-reverse-phase-protein-array-technology-advancing-precision-oncology-strategies
#13
REVIEW
Mari Masuda, Riko Nakagawa, Tadashi Kondo
The last few decades have seen remarkable strides in the field of cancer therapy. Precision oncology coupled with comprehensive genomic profiling has become routine clinical practice for solid tumors, the advent of immune checkpoint inhibitors has transformed the landscape of oncology treatment, and the number of cancer drug approvals has continued to increase. Nevertheless, the application of genomics-driven precision oncology has thus far benefited only 10%-20% of cancer patients, leaving the majority without matched treatment options...
February 26, 2024: Cancer Science
https://read.qxmd.com/read/38373689/cd24-negativity-reprograms-mitochondrial-metabolism-to-ppar%C3%AE-and-nf-%C3%AE%C2%BAb-driven-fatty-acid-%C3%AE-oxidation-in-triple-negative-breast-cancer
#14
JOURNAL ARTICLE
Divya Murthy, Debasmita Dutta, Kuldeep S Attri, Tagari Samanta, Sukjin Yang, Kwang Hwa Jung, Sarah G Latario, Vasanta Putluri, Shixia Huang, Nagireddy Putluri, Jun Hyoung Park, Benny Abraham Kaipparettu
CD24 is a well-characterized breast cancer (BC) stem cell (BCSC) marker. Primary breast tumor cells having CD24-negativity together with CD44-positivity is known to maintain high metastatic potential. However, the functional role of CD24 gene in triple-negative BC (TNBC), an aggressive subtype of BC, is not well understood. While the significance of CD24 in regulating immune pathways is well recognized in previous studies, the significance of CD24 low expression in onco-signaling and metabolic rewiring is largely unknown...
February 17, 2024: Cancer Letters
https://read.qxmd.com/read/38367548/abcb1-dependent-collateral-sensitivity-of-multidrug-resistant-colorectal-cancer-cells-to-the-survivin-inhibitor-mx106-4c
#15
JOURNAL ARTICLE
Zi-Ning Lei, Najah Albadari, Qiu-Xu Teng, Hadiar Rahman, Jing-Quan Wang, Zhongzhi Wu, Dejian Ma, Suresh V Ambudkar, John N D Wurpel, Yihang Pan, Wei Li, Zhe-Sheng Chen
AIMS: To investigate the collateral sensitivity (CS) of ABCB1-positive multidrug resistant (MDR) colorectal cancer cells to the survivin inhibitor MX106-4C and the mechanism. METHODS: Biochemical assays (MTT, ATPase, drug accumulation/efflux, Western blot, RT-qPCR, immunofluorescence, flow cytometry) and bioinformatic analyses (mRNA-sequencing, reversed-phase protein array) were performed to investigate the hypersensitivity of ABCB1 overexpressing colorectal cancer cells to MX106-4C and the mechanisms...
February 6, 2024: Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
https://read.qxmd.com/read/38263609/lrp8-promotes-tumorigenesis-in-ovarian-cancer-through-inhibiting-p53-signaling
#16
JOURNAL ARTICLE
Yan Xu, Yang Zhou, Xiling Yi, Xiaocui Nie
Ovarian cancer (OC) is the most lethal gynecological malignancy with a high mortality rate. Low-density lipoprotein (LDL) receptor-related protein 8 (LRP8) is a cell membrane receptor belonging LDL receptor family and is involved in several tumor progressions. However, there is limited understanding of how LRP8 mediates OC development. LRP8 expression level was identified in human OC tissues and cells using immunohistochemical staining and quantitative polymerase chain reaction assays, respectively. Functions of LRP8 in OC progression were evaluated by Celigo cell counting, wound healing, transwell and flow cytometry assays, and the xenograft models...
January 23, 2024: Cell Biology International
https://read.qxmd.com/read/38254014/mapping-three-dimensional-intratumor-proteomic-heterogeneity-in-uterine-serous-carcinoma-by-multiregion-microsampling
#17
JOURNAL ARTICLE
Allison L Hunt, Nicholas W Bateman, Waleed Barakat, Sasha C Makohon-Moore, Tamara Abulez, Jordan A Driscoll, Joshua P Schaaf, Brian L Hood, Kelly A Conrads, Ming Zhou, Valerie Calvert, Mariaelena Pierobon, Jeremy Loffredo, Katlin N Wilson, Tracy J Litzi, Pang-Ning Teng, Julie Oliver, Dave Mitchell, Glenn Gist, Christine Rojas, Brian Blanton, Kathleen M Darcy, Uma N M Rao, Emanuel F Petricoin, Neil T Phippen, G Larry Maxwell, Thomas P Conrads
BACKGROUND: Although uterine serous carcinoma (USC) represents a small proportion of all uterine cancer cases, patients with this aggressive subtype typically have high rates of chemotherapy resistance and disease recurrence that collectively result in a disproportionately high death rate. The goal of this study was to provide a deeper view of the tumor microenvironment of this poorly characterized uterine cancer variant through multi-region microsampling and quantitative proteomics. METHODS: Tumor epithelium, tumor-involved stroma, and whole "bulk" tissue were harvested by laser microdissection (LMD) from spatially resolved levels from nine USC patient tumor specimens and underwent proteomic analysis by mass spectrometry and reverse phase protein arrays, as well as transcriptomic analysis by RNA-sequencing for one patient's tumor...
January 22, 2024: Clinical Proteomics
https://read.qxmd.com/read/38228924/endosomal-recycling-inhibitors-downregulate-estrogen-receptor-alpha-and-synergise-with-endocrine-therapies
#18
JOURNAL ARTICLE
Kelsey A Fletcher, Mai H Alkurashi, Andrew J Lindsay
PURPOSE: Breast cancer (BC) accounts for roughly 30% of new cancers diagnosed in women each year; thus, this cancer type represents a substantial burden for people and health care systems. Despite the existence of effective therapies to treat BC, drug resistance remains a problem and is a major cause of treatment failure. Therefore, new drugs and treatment regimens are urgently required to overcome resistance. Recent research indicates that inhibition of the endosomal recycling pathway, an intracellular membrane trafficking pathway that returns endocytosed proteins back to the plasma membrane, may be a promising strategy to downregulate clinically relevant cell surface proteins such as HER2 and HER3, and to overcome drug resistance...
January 16, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38191060/target-genes-regulated-by-clec16a-intronic-region-associated-with-common-variable-immunodeficiency
#19
JOURNAL ARTICLE
Xubo Huang, Jinxia Huang, Xiumei Li, Jingxian Fan, Desheng Zhou, Hui-Qi Qu, Joseph T Glessner, Dandan Ji, Qi Jia, Zhiyong Ding, Nan Wang, Wei Wei, Xing Lyu, Mulin Jun Li, Zhe Liu, Wei Liu, Yongjie Wei, Hakon Hakonarson, Qianghua Xia, Jin Li
BACKGROUND: CLEC16A intron 19 has been identified as a candidate locus for common variable immunodeficiency (CVID). OBJECTIVE: The objective of this study is to elucidate the molecular mechanism by which variants at the CLEC16A intronic locus may contribute to the pathogenesis of CVID. METHODS: We performed fine-mapping of the CLEC16A locus in a CVID cohort, then deleted the candidate functional SNP in T-cell lines by the CRISPR-Cas9 technique and conducted RNA-seq to identify target gene(s)...
January 6, 2024: Journal of Allergy and Clinical Immunology
https://read.qxmd.com/read/38187700/phosphorylation-regulates-tau-s-phase-separation-behavior-and-interactions-with-chromatin
#20
Lannah S Abasi, Nesreen Elathram, Manasi Movva, Amar Deep, Kevin D Corbett, Galia T Debelouchina
Tau is a microtubule-associated protein often found in neurofibrillary tangles (NFTs) in the brains of patients with Alzheimer's disease (AD). Beyond this context, mounting evidence suggests that tau localizes into the nucleus, where it may play a role in DNA protection and heterochromatin regulation. Models of tau depletion or pathology show loss of genetically silent heterochromatin, aberrant expression of heterochromatic genes, and transposable element activation. The molecular mechanisms behind these observations are currently unclear...
December 23, 2023: bioRxiv
keyword
keyword
79090
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.